Low CAVIN3 expression was associated with better radiotherapy response in cervical cancer
Low CAVIN3 expression was associated with higher treatment response and substantially longer progression-free survival after radiotherapy for cervical cancer.
Tag
preliminary
Low incidental brain doses were not linked to early cognitive decline after head and neck radiotherapy
Regional brain dose showed no significant association with cognition through 12 months, although only 24 patients completed one-year testing.
Three clinical variables predicted moderate-to-severe esophagitis during esophageal cancer radiotherapy
Tumor location, hypertension and albumin predicted moderate-to-severe acute esophagitis with an internally validated AUC of 0.816.
FLASH and conventional irradiation triggered similar mitochondrial remodeling in head and neck cancer cells
Both dose rates increased mitochondrial respiration after irradiation, with no clear FLASH-specific mitochondrial phenotype under normoxic conditions.
Bullous pemphigoid developed during breast radiotherapy with concurrent pembrolizumab
Bullous pemphigoid emerged after seven radiotherapy fractions during pembrolizumab, spreading beyond the treatment field and ultimately preventing completion of both therapies.
Ultra-high dose-rate proton DNA damage changed with scavenger concentration and dose
Ultra-high dose-rate protons produced fewer DNA breaks at low scavenger concentration, but the effect diminished or reversed under other experimental conditions.
Baseline extracellular-vesicle microRNAs were associated with breast radiotherapy toxicity
Baseline miR-144-5p and miR-222-3p differed in patients who later developed greater radiation toxicity, but the signals require validation.
Iridium-192 boost improved progression-free survival in unresectable hilar cholangiocarcinoma
An iridium-192 boost increased median progression-free survival from 8.6 to 11.2 months, without a significant overall-survival improvement.
Prototype brachytherapy devices combined local radiation, hyperthermia and drug delivery concepts
A prototype stent increased dislodgement resistance 15-fold and demonstrated controllable heating, but proposed radiation-dose benefits remain experimentally untested.
Longitudinal muscle loss and myocardial remodeling tracked worse survival after non-small cell lung cancer radiotherapy
Skeletal muscle loss and substantial left ventricular mass changes on follow-up imaging were strongly associated with poorer survival after curative radiotherapy.
Daily adaptation supported 17-fraction definitive chemoradiotherapy for cervical cancer
Daily online adaptation improved pelvic target coverage during 17-fraction cervical chemoradiotherapy, with 10% grade ≥3 gastrointestinal toxicity.
CHAF1A promotes DNA repair and tumor radioresistance through RAD51 and KU70
CHAF1A supported homologous recombination and non-homologous end joining, while its depletion increased radiosensitivity in xenograft models.
Chemoradiotherapy and immunoradiotherapy reshape distinct esophageal cancer microenvironment programs
Chemoradiotherapy suppressed LAMC2–macrophage signalling, while immunoradiotherapy enriched CCL5-positive CD8 T cells in preclinical esophageal squamous-cell carcinoma models.
Interpretable AI separated three-year anal cancer relapse risk after chemoradiotherapy
An explainable model separated three-year local relapse rates of 11% versus 39%, but lacks independent external validation.
Radiotherapy-specific nutrition screening tool showed high agreement with established assessments
NRS-RT showed 92.9% sensitivity and 97.2% specificity versus NRS-2002, but requires external validation before clinical adoption.